Hypertension and Prostanoid Signaling in the Subfornical Organ of the Brain

大脑穹窿下器官中的高血压和前列腺素信号传导

基本信息

  • 批准号:
    7760718
  • 负责人:
  • 金额:
    $ 36.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-05 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

PROJECT 1 (Davisson): Hypertension and prostanoid signaling in the subfornical organ of the brain There is compelling evidence that human hypertension is characterized by neurohumoral dysfunction, and inappropriate angiotensin II (Angll) signaling in the CNS is a primary culprit. The subfornical organ (SFO), a forebrain structure considered a key "gateway" to the CNS for circulating Angll, provides extensive inputs to the paraventricular nucleus (PVN) and its output neurons mediating sympathetic activation and release of hormones, e.g., vasopressin. Our work shows that excessive reactive oxygen species (ROS) signaling in SFO are critical in "slow-pressor" Angll hypertension, a subpressor Angll infusion model that recapitulates critical features of essential hypertension. However, the signaling mechanisms within the SFO by which Angll and oxidant products initiate the neurohumoral dysfunction leading to the blood pressure elevation are not clear. Cyclooxygenase (COX)-derived prostaglandins, such as prostaglandin E2 (PGE2), have long been implicated in the signaling pathways of Angll, but their role in critical mechanisms in the SFO underlying slow-pressor Angll hypertension has not been elucidated. Our preliminary data suggest a crucial role of COX-1-derived PGE2 acting on PGE2 EPi receptors (EPiR) in Angll slow pressor hypertension. Project 1 will test the central hvpothesis that PGE9 provides an essential link between Angll, ROS and the maladaptive changes that occur in the SFO-PVN axis which lead to neurohumoral dysfunction in the Ang-ll slow-pressor model. Aim 1 will test the hypothesis that AT, receptors, NADPH oxidase subunits and PGE2-related molecules are co-localized in PVN-projecting SFO neurons in a manner consistent with their functional interaction. Aim 2 will test the hypothesis that administration of slow pressor doses of Angll elicits C0X1- dependent PGE2 production in the SFO. This aim will also determine whether ROS production is upstream or downstream of PGE2. Aim 3 will use single-cell electrophysiology and ROS imaging to test the hypothesis that COX-1-derived PGE2 is required for the enhancement of Ca^* currents and ROS production induced by Angll in PVN-projecting SFO neurons. Aim 4 will test the hypothesis that EPiR in SFO are necessary and sufficient to confer susceptibility to slow-pressor Angll neurohumoral dysfunction and hypertension. We will use a newly developed conditional EPiR null mouse in which EPiR expression can be regionally reconstituted by local delivery of Cre recombinase.
项目1 (Davisson):高血压和脑皮层下器官的前列腺素信号

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robin L Davisson其他文献

Robin L Davisson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robin L Davisson', 18)}}的其他基金

Radiotelemetry Core
无线电遥测核心
  • 批准号:
    7760730
  • 财政年份:
    2009
  • 资助金额:
    $ 36.07万
  • 项目类别:
Brain Ang. in Obesity-Induced Hypertension: Role of ER, Oxidant, & Leptin Stress
脑昂.
  • 批准号:
    8524229
  • 财政年份:
    2007
  • 资助金额:
    $ 36.07万
  • 项目类别:
Brain Ang. in Obesity-Induced Hypertension: Role of ER, Oxidant, & Leptin Stress
脑昂.
  • 批准号:
    8651936
  • 财政年份:
    2007
  • 资助金额:
    $ 36.07万
  • 项目类别:
Role of Redox-Mediated Activation of NFkappaB and AP-1 in Neurogenic Hypertension
氧化还原介导的 NFkappaB 和 AP-1 激活在神经源性高血压中的作用
  • 批准号:
    7876841
  • 财政年份:
    2006
  • 资助金额:
    $ 36.07万
  • 项目类别:
Role of Redox-Mediated Activation of NFkappaB and AP-1 in Neurogenic Hypertension
氧化还原介导的 NFkappaB 和 AP-1 激活在神经源性高血压中的作用
  • 批准号:
    7643152
  • 财政年份:
    2006
  • 资助金额:
    $ 36.07万
  • 项目类别:
Role of Redox-Mediated Activation of NFkappaB and AP-1 in Neurogenic Hypertension
氧化还原介导的 NFkappaB 和 AP-1 激活在神经源性高血压中的作用
  • 批准号:
    7278272
  • 财政年份:
    2006
  • 资助金额:
    $ 36.07万
  • 项目类别:
Role of Redox-Mediated Activation of NFkappaB and AP-1 in Neurogenic Hypertension
氧化还原介导的 NFkappaB 和 AP-1 激活在神经源性高血压中的作用
  • 批准号:
    7081575
  • 财政年份:
    2006
  • 资助金额:
    $ 36.07万
  • 项目类别:
Role of Redox-Mediated Activation of NFkappaB and AP-1 in Neurogenic Hypertension
氧化还原介导的 NFkappaB 和 AP-1 激活在神经源性高血压中的作用
  • 批准号:
    7439024
  • 财政年份:
    2006
  • 资助金额:
    $ 36.07万
  • 项目类别:
Oxidative stress in hypertension induced cardiac hypertrophy: RAS system
高血压引起的心脏肥大中的氧化应激:RAS系统
  • 批准号:
    6843766
  • 财政年份:
    2004
  • 资助金额:
    $ 36.07万
  • 项目类别:
Regional and cellular significance of brain renin angio
脑肾素血管的区域和细胞意义
  • 批准号:
    6704841
  • 财政年份:
    2003
  • 资助金额:
    $ 36.07万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 36.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 36.07万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 36.07万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 36.07万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 36.07万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 36.07万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 36.07万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 36.07万
  • 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 36.07万
  • 项目类别:
    Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 36.07万
  • 项目类别:
    Idea to Innovation
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了